Please assess the completion status of the following clinical trial:

Trial Title: A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 18 or older and sign written informed consent.~* Must be wiling and able to comply with protocol.~* Must have active seborrheic dermatitis of the face.~Exclusion Criteria:~* No history of overt bacterial, viral or fungal infection of the head/neck.~* No history or presence of compromising dermatosis elsewhere on the skin~* No Parkinson's disease, HIV, infections or disorders of the central nervous system~* No actinically damaged skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Elidel Cream (pimecrolimus) (Type: EXPERIMENTAL): Elidel Cream to be applied twice daily for 4 weeks
- Ketoconazole Cream (Nizoral) (Type: ACTIVE_COMPARATOR): Ketoconazole Cream to be applied twice daily for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).